DA Davidson raised the firm’s price target on Prestige Consumer to $65 from $60 and keeps a Neutral rating on the shares after its Q3 sales and earnings beat. The company’s growth was driven by the International business and sales in the Eye & Ear Care category, which were up 19% from last year, including up 18% in North America, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PBH:
- Prestige Consumer management to meet with Oppenheimer
- Prestige Consumer price target raised to $80 from $79 at Canaccord
- Prestige Consumer Healthcare Begins Sharing Financial Results
- Prestige Consumer raises FY24 EPS view to $4.33 from $4.27-$4.32
- Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results
